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Abstract: 
Background: Anticoagulants are the class of drugs that are used to prevent thrombus extension and embolic 
complications by reducing the rate of fibrin formation. They do not dissolve already formed clot but prevent 
recurrences. 
Method: A total of 200 patients were included in these prospective, uni-centric, observational studies who were 
suffering from Cardiovascular Diseases, from the cardiology inpatient department at a tertiary care hospital in 
Bangalore.  
Results: It was observed that out of 200 patients included in the study, 122 (61%) patients were treated with 
anticoagulants and antiplatelets, 75(37.5%) were treated with anticoagulants only. Out of 200 prescriptions 
encountered, 198 (99%) prescriptions have rational use of anticoagulants and only 2 (1%) were irrational. It 
was also observed that only 0.5% was present with GI bleeding whereas 2% of the total population was present 
with other side effects like nasal bleeding, haematuria, etc.  Among 200 prescriptions, 251 drug interactions 
were found with anticoagulants. where Heparin and Aspirin was the most frequently encountered (23.1%) 
interaction, The least (0.4%) seen drug interactions were Aspirin & Warfarin, Heparin & Eptifibatide, 
Enoxaparin & Eptifibatide, Heparin & Tirofiban, Heparin & Enoxaparin, Warfarin & Tramadol, Warfarin & 
Amoxicillin & Glipizide and Heparin. 
 Keywords: GI Bleeding, Anticoagulants 
Corresponding author:  
Fereshteh Jaferi,  
Dayananda Sagar College of Pharmacy,  
Kumaraswamy layout, Bangalore-78               
E-Mail: Fereshtehjaferi@gmail.com 
 
Please cite this article in press as Fereshteh Jaferi et al, A Prospective Study on Gastric Bleeding and Drug 
Interactions Associated With Anticoagulant Therapy at Cardiology Department of a Tertiary Care Hospital, 
Indo Am. J. P. Sci, 2017; 4(11). 
 
 
 
 
QR code 
 
 
IAJPS 2017, 4 (11), 3991-3998                 Fereshteh Jaferi et al                   ISSN 2349-7750 
 
 w w w . i a j p s . c o m  
 
Page 3992 
INTRODUCTION: 
Anticoagulants are the drugs used to prevent 
thrombus extension and embolic complications by 
reducing the rate of fibrin formation. They do not 
dissolve already formed clot but prevent 
recurrences. In a hospital setting anticoagulants are 
mainly used for the following indications like deep 
vein thrombosis (DVT), pulmonary embolism (PE), 
myocardial infarction (MI), unstable angina, 
rheumatic heart disease, vascular surgery, 
prosthetic heart valve, retinal vessel thrombosis, 
extra corpuscular circulation, haemodialysis and 
defibrination syndrome[1]. Heparin, one of the 
oldest drugs still in widespread clinical use, is a 
naturally occurring glycosaminoglycan whose main 
function is to inhibit the coagulation of blood. It 
was discovered almost a century ago and took 
many years to move from the laboratory to the 
bedside [2]. Unfractionated heparin (UFH) binds to 
and increases the activity of antithrombin III by 
inducing a conformational change to factor Xa, 
which ultimately leads to inhibition at Xa and IIa in 
a1:1 ratio. Unfractionated heparin also has some 
inhibition on factors IXa, XIa, XIIa. Low molecular 
weight heparins (LMWs), which also bind AT3, are 
smaller and have a higher proportional impact on 
Xa, versus IIa, in a 3:1 or 2:1 ratio. Unlike 
warfarin, UFH is administered parenterally, both 
subcutaneous for its prophylaxis use and as a 
continuous intravenous infusion when used 
therapeutically. UFH has much faster onset of 
action as compared to warfarin; when used 
intravenously, while therapeutic efficacy is reached 
within 20-60 minutes when administered 
subcutaneously. The LMWH are parenterally-
administered drugs, and include dalteparin, 
enoxaparin and tinzaparin. The LMWHs are 
administered at a fixed dose, based on total body 
weight. These drugs have near 100% 
bioavailability and reached peak levels 2-4 hours 
after subcutaneous administration. They have a 
half-life of 3-4 hours and are eliminated primarily 
(80%) via renal clearance, this necessitating dose 
reduction considerations in patients with renal 
insufficiency [3]. Vitamin K antagonists exert their 
anticoagulant effects by inhibiting hepatic 
production and depleting vitamin dependent 
clotting factors, especially clotting factor II 
(thrombin), VII, IX and X. The time to onset and 
offset of the anti-coagulant effect of warfarin is 
long because of the long half-lives of these vitamin 
K- dependent clotting factors, specially clotting 
factor II. Dabigatran directly inhibits activated 
clotting factor II (IIa), and rivaroxaban, apixaban 
and edoxaban directly inhibit activated clotting 
factor X (Xa) activity [4]. Throughout the world 
high morbidity and mortality is associated with 
cardiovascular diseases [5]. The risk factors for 
cardiovascular diseases are multiple such as 
elevated cholesterol and blood pressure levels, 
excessive smoking habits, diabetes, malnutrition 
and fatness, etc [6]. The treatment for coronary 
artery disease involves the use of various categories 
of drugs namely anti-platelet drugs, anticoagulants, 
anti-anginal drugs, beta-blockers, angiotensin 
converting enzyme inhibitors (ACEI)/ angiotensin 
II receptor blockers (ARBs), calcium channel 
blockers, diuretics, etc [7]. Drug utilization pattern 
study is a powerful exploratory tool which is a 
descriptive and analytical method of collection, 
quantification, understanding and evaluation of the 
prescription pattern, as well as dispensing and 
consumption for the advancement of existing 
therapy and enhancement of patient safety. Triad of 
right diagnosis, accurate prescription and excellent 
patient counselling leads to the effective and safe 
use of drug [8]. There is a need to record major 
bleeds in order to assess the safety of a new 
antithrombotic therapy. Especially prior to 
regulatory approval, counting major bleeds will 
allow detecting a signal for enhanced bleeding risk 
early during the course of clinical development of a 
new antithrombotic regime. Threatening bleeds, 
events that cause permanent organ damage and 
bleeds requiring acute intervention or operation to 
stabilize the patient, major bleeds also compromise 
asymptomatic haemoglobin drop of 2 or 3 gm/dl 
combined with a small access site or nasal bleed. 
The important risk factor for haemorrhage is the 
intensity of the anticoagulant effect. Studies 
indicate that with a target INR of ˃3.0 the 
incidence of major bleeding is two-fold greater 
compared to those with a target INR of 2.0-3.0. The 
combined use of VKAs and non-steroidal anti-
inflammatory drugs may result in an 11-fold higher 
risk of hospitalization for gastro-intestinal bleeding 
as compared with the general population [9]. 
Moreover, practice guidelines by gastrointestinal 
professional societies only marginally address this 
topic as they mostly focus on management of 
anticoagulants in patients undergoing elective 
procedures. This paucity of data is even more 
relevant for direct oral anticoagulants [10]. Most of 
the haemorrhage risk schemes were developed 
from cohorts of patients newly prescribed or 
already taking anticoagulants, and as such reflects 
patients who were considered suitable for 
anticoagulation therapy. Several risk schemes were 
specifically developed in patients with atrial 
fibrillation and others in cohorts of venous 
thromboembolism and so some risk scores contain 
disease-specific risk factors. The Outpatient 
Bleeding Risk Index (OBRI) was the only one that 
had a mixed group of indications for 
anticoagulation and was primarily developed in a 
group of patient’s newly starting warfarin for 
cardiac surgery/prosthetic heart valves [11]. In 
making a decision regarding whether to include 
new oral anticoagulant on the formulary, decision 
makers need to balance the benefit and the harm 
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associated with each therapeutic choice [12] the 
aim of this study was to evaluate the potential 
impact of the use of the new anticoagulants 
dabigatran and rivaroxaban in the local hospital 
setting for the prevention of venous 
thromboembolism (VTE) and stroke in patients 
with atrial fibrillation (SPAF), and subsequent 
estimate the costs involved [13]. 
 
METHODOLOGY: 
STUDY SITE: a Tertiary Care Hospital in 
Bangalore 
STUDY PERIOD: 6 months 
STUDY DESIGN: Hospital based prospective 
study 
SOURCES OF DATA: 
a) Patient’s case sheets 
b) Medication charts 
c) Lab reports 
d) Patients’/ attendants’ interview 
 STUDY CRITERIA 
 Inclusion Criteria    
 All individuals of either sex above 18 
years of age 
 Diagnosed with cardiovascular 
complications 
 Those  who are on anticoagulant therapy 
Exclusion criteria 
 Patients on dialysis receiving 
Anticoagulants 
 Patients with incomplete case records 
form 
 
This is a prospective, unicentric, observational 
study conducted in 200 patients suffering from 
Cardiovascular Disease (CVD) at Cardiology 
Inpatient (IP) department of a tertiary care hospital. 
The study protocol was approved by the 
Institutional Ethics Committee Board (IECB). A 
suitable data collection form was designed 
(Annexure 1) to collect and document the data. 
Data collection form included the provision for 
collection of information related to socio-
demographic details of the patients, pertaining to 
age, gender, family history, BMI, education status, 
place of stay, smoking status, daily alcohol 
consumption, assessment of diet were obtained and 
recorded. The prescription pattern of Anticoagulant 
drugs was assessed using WHO prescribing 
indicators. The prescribing indicators that were 
measured include: The average number of drugs 
prescribed per encounter was calculated to measure 
the degree of polypharmacy. It was calculated by 
dividing the total number of different drug products 
prescribed by the number of encounter surveyed. 
Combinations of drugs prescribed for one health 
problem were counted as one. Percentage of drugs 
prescribed by generic name is calculated to 
measure the tendency of prescribing by generic 
name. It was calculated by dividing the number of 
drugs prescribed by generic name by total number 
of drugs prescribed, multiplied by 
100. Percentage of drugs from an essential drug 
list (EDL) was calculated to measure the degree to 
which practices conform to a national drug policy 
as indicated in the national drug list of WHO. 
Percentage is calculated by dividing number of 
products prescribed which are in essential drug list 
are by the total number of drugs prescribed 
multiplied by 100.              
 Statistical Analysis: Microsoft Excel software 
was used to analyse the data. 
 
RESULTS:        
I. Socio-Demographic Details 
a) Age details  
In our study, mean age was found to be 
60.3±12.4years.The highest number of male 
(28.3%) were in the age group of 58-67 years. The 
highest numbers of female (26.9%) were in the age 
group of 58-67 years. 
 
 
Fig 1: Pie chart representation of age distribution in our study population 
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b) Past medical history 
In our study population, 33% of patients are present with HTN, 69% with IHD, 5% with CVA and 35.5% with 
MI.    
 
 
Fig 2: Bar chart representation of past medical history of CVD in our study population 
 
II) Anticoagulant prescribing pattern: in our 
study population 37.5% were prescribed with 
monotherapy and 61% were prescribed as 
combination with antiplatelets
. 
 
 
Fig 3:  Pie chart representation of anticoagulant prescribing pattern 
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III) Various classes of drugs 
 
 
Fig 4: presentation of different classes of drugs 
 
IV) SIDE EFFECTS 
i)  GI bleeding:  In our study population, it is observed that only 0.5% were present with GI bleeding. 
 
population
0.50%
99.50%
GI BLEEDING 
Present
Absent 
 
 
IAJPS 2017, 4 (11), 3991-3998                 Fereshteh Jaferi et al                   ISSN 2349-7750 
 
 w w w . i a j p s . c o m  
 
Page 3996 
Fig 5: Pie chart representation incidences of GI bleeding in the study 
ii) Other side effects   : In our study population, 2% of the total population was present with other side effects 
like nasal bleeding, haematuria, etc. 
 
 
Fig 6: Pie chart representation of side effects observed in study population 
 
V. PHARMACIST INTERVENTION 
 Drug-drug interaction 
Among 200 prescriptions, 251 drug interactions 
were found. Heparin and Aspirin were most 
frequently encountered (23.1%) drug interaction. 
The least (0.4%) seen drug interactions were 
Aspirin and Warfarin, Heparin and Eptifibatide, 
Enoxaparin and Eptifibatide, Heparin and 
Tirofiban, Heparin+ Enoxaparin, Warfarin and 
Tramadol, Warfarin and Amoxicillin and Glipizide 
and Heparin. 
 
 
Fig 7: Pie chart representation of drug interaction with other drugs 
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Out of 296 drug interactions the highest (7.8%) was found between Aspirin and Clopidogrel, the second highest 
(4.4%) drug interaction was found between Furosemide and Metoprolol. 
 
 DISCUSSION: 
The mean age of the patients with Cardiovascular 
Disease (CVD) in our study population were found 
to be 60.3±12.4 years (Figure 1). Among 200 
patients studied, 58(52.5%) patients presented with 
hypertension, 138(69%) presented with ischaemic 
heart disease, 10(5%) patients presented with CVA, 
71(35.5%) patients were suffering from myocardial 
infarction. (Figure2). Earlier studies reported that 
among 112 patients enrolled, 84.82% had 
hyperlipidemia followed by hypertension (80.35%) 
and ischaemic heart disease(66.69%).12 It was also 
reported that 105(46.46%) were on anticoagulants 
among which 96(40.26%) received enoxaparin 
sodium, 5(2.21%) received Heparin and 4(1.76%) 
received Acenocoumarol. The details of the 
prescribing pattern of anticoagulants when assessed 
showed 75(37.5%) were prescribed with 
anticoagulant as monotherapy, 122(61%) were 
prescribed anticoagulant along with an 
antiplatelet.12 3(5.8%) females were prescribed 
with triple therapy in combination of two 
anticoagulants and one antiplatelet drug. (Figure 3). 
In a similar study it was found that 63(84%) 
patients received only one anticoagulant during 
their hospitalization. 21(16%) patients received 
more than one anticoagulant. This combination 
therapy included parental and oral drugs or 
combination of two or more drugs administered 
orally. Most common combination therapy was 
Acenocoumarol and Enoxaparin, Acenocoumarol   
and Heparin followed by Enoxaparin and Heparin 
and Warfarin, Enoxaparin and Acenocoumarol and 
Heparin, Enoxaparin and Warfarin, Enoxaparin and 
Heparin was used in hospital. 1 it was observed the 
distribution pattern of various drugs along with 
anticoagulant drug therapy. among these the most 
commonly prescribed were Antihypertensive 
147(10.9%) followed by Antihyperlipidemics 
144(10.7%).it was also observed Hepatoprotectants 
and Immunosuppressants 1(0.1%) were least 
prescribed. ( Figure 4 ).In a similar study, among 
170  patients, it was seen that Antiplatelets 
(99.41%) were most commonly given, followed by 
Antihyperlipidemics (95.29%) and 
Antihypertensives (64.71%).13 In our study 
population, it was observed that only 1(0.5%) of 
the total study population presented with GI 
bleeding as a side effects whereas it was absent in 
the 199 (99.5%) of the remaining population.( 
Figure 5). 4(2%) of the total study population 
presented with other side effects like bleeding, 
haematuria whereas it was absent in  rest of the 
196(98%) of the study population (Figure 6). When 
overall interaction of the drug in the prescription 
were assessed, 296 drug interactions were found  
where the highest occurring major interaction was 
Aspirin and Clopidogrel 20(9.1%)  followed by  
Furosemide and Metoprolol with highest occurring 
moderate interaction effect accounting 
12(5.5%)and 1(1.3%) in male and female (Fig7 ).  
 
CONCLUSION: 
In the present study, the prevalence of CVD was 
high with increasing age. The male patients with an 
age group of 58-67years were most affected. The 
use of AC and antiplatelet combination was seen in 
most of the patients which adds a value in the 
effective treatment as well as prevention of IHD. 
Various potential drug interactions were 
encountered in the   prescription.  
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